Gülmez, AhmetHakan, Harputluoglu2024-08-042024-08-0420222602-3164https://doi.org/10.14744/ejmi.2022.65683https://search.trdizin.gov.tr/yayin/detay/1133716https://hdl.handle.net/11616/88920Objectives: This study aimed to retrospectively investigate the rate of pathological complete response (pCR) and markers predicting this response for trastuzumab and pertuzumab-containing regimens compared to trastuzumabcontaining regimens for stage II to III HER-2 positive breast cancer (BC). Methods: In this study, we retrospectively analyzed the data of patients with Her-2 positive advanced BC who were treated with trastuzumab or trastuzumab and pertuzumab in addition to neoadjuvant chemotherapy. Patients were classified according to their pre-treatment clinical stages, hormone receptor status, Her-2 immuno-histochemical score, ki-67 index, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) ratio. Results: For NLR, it was 1.9±0.85 in patients with pCR and 2.4±0.83 in patients without pCR. For PLR it was 112±53.3 and 129.4±36.2, respectively. For PNI, it was 51.6±5.8 and 48.1±5.9. Low NLR and PLR as well as high PNI were significantly associated with pCR. In addition, the pCR of patients with hormone receptor negativity and dual Her-2 blockade was statistically significant. Conclusion: This is the first study in the literature to show that prognostic scores such as NLR, PLR, and PNI have statistically significant benefits on pCR in patients treated with the neoadjuvant dual blockade.eninfo:eu-repo/semantics/openAccessArticle6441742310.14744/ejmi.2022.656831133716